Improvements in Frailty Care as Cost Effective

By Staff Writer

January 15, 2024

Frailty care improvements

Frail patients require a robust system during hospital admission to decrease deconditioning risk and hasten discharge. In recent years, a significant effort has gone into quickly identifying these patients. Specialists evaluate them as part of a Frailty Liaison Team. This study examines the effect of these metrics on patient outcomes, as published in the Future Healthcare Journal. 

The Importance of Locating and Transferring Patients at an Early Stage

According to the findings of previous research, proposed internal transfers frequently face delays or may not take place at all. In 2017, hospitals moved three-fifths of fragile patients to appropriate wards. These delays likely influence the duration of hospital stays. This assumption is based on the specialised care frailty units provide. 

A Discussion of the Research Methodology

The Frailty Liaison Team performs the Comprehensive Geriatric Assessment (CGA) on patients classified as frail. These patients receive treatment on the Clinical Decisions Unit (CDU) or the Acute Medical Unit (AMU). This study compares the length of stay for patients transferred to a frailty ward on the assessment day with those transferred after 24 hours. 

The findings of the research study

According to the findings of the study, early transfers result in a hospital stay that is reduced by more than one day. This results in a reduction in direct costs as well as a reduction in the patient’s exposure toward harm that is associated with the hospital. According to this study frailty care improvements could lead to potential annual saving of £26,640.

The Consequences That the Study Could Have

Because of the favourable findings of the study, conversations have begun regarding the possibility of improving the local frailty route. The authors will use the data to identify potential improvements in patient care and compare different discharge procedures. 

The findings of this study emphasise the need of identifying frail individuals at an early stage and transferring them to specialised wards to receive treatment. They have the potential to greatly enhance patient outcomes while also lowering the expense of healthcare. 

 

Reference url

Recent Posts

lenacapavir HIV PrEP access
    

Global Health Partnerships Unite to Expand Access to Lenacapavir for HIV Prevention

💉 How can we ensure equitable access to HIV prevention methods like lenacapavir?

A recent initiative from the Global Fund, supported by key global health organizations, aims to provide affordable access to this new HIV pre-exposure prophylaxis medication.

With a goal to reach 2 million individuals over three years, this coordinated effort seeks to drastically cut HIV infections and align with our commitment to ending AIDS by 2030.

Explore the details of this impactful collaboration and how it could transform HIV prevention.

#SyenzaNews #globalhealth #HealthcareInnovation #MarketAccess

antimicrobial resistance africa
     

Africa’s Health Crisis: Antimicrobial Resistance and Mpox Outbreak

🌍 Are we prepared to tackle the hidden pandemic of antimicrobial resistance (AMR) in Africa?

With AMR rapidly becoming a dominant health crisis, it’s critical to understand its impact on our healthcare systems and most vulnerable populations.

The Africa CDC highlights the urgent need for substantial investment and coordinated responses to combat this escalating threat, alongside the ongoing Mpox outbreak.

Discover the pressing challenges and potential solutions in our latest article.

#SyenzaNews #GlobalHealth #HealthcareInnovation #AntimicrobialResistance #PublicHealth

BioSapien cancer drug delivery
    

BioSapien Innovative Cancer Drug Delivery Solutions

🌟 How is innovation in drug delivery shaping the future of cancer treatment? 🌟

Discover how UAE-based BioSapien is transforming the healthcare landscape with the MediChip™ platform, securing $5.5 million in pre-Series A funding to enhance cancer care.

This innovative solution promises to minimise side effects and improve treatment outcomes for patients, fully embracing the potential of biotechnology in the fight against cancer.

Read more about BioSapien’s journey and its impact on global health!

#SyenzaNews #biotechnology #oncology #innovation #HealthTech

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2024 Syenza™. All rights reserved.